
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

INC research expands presence in Japan with new Osaka office

May 26, 2016 | News | By BioSpectrum Bureau

INC research expands presence in Japan with new Osaka office



INC Research Holdings Inc, a leading, global phase I to IV contract research organization (CRO), has announced the relocation and expansion of its Osaka, Japan office in support of the company's long-term growth strategy both in Japan and across the Asia Pacific region.

Since the beginning of 2015 INC Research's Japanese operations have more than tripled their employee headcount and expect continued strong growth. The new Osaka office further expands the company's presence in the Asia Pacific region to provide its global drug development customers with expanded access to Japan, the world's second largest pharmaceutical market and a valued destination for regional and global clinical trials. The Company's presence in Japan also is supported by an office in the Shinagawa ward in Tokyo.

"Since establishing a strategic R&D presence in Japan, INC Research has experienced an exciting and notable period of initial growth," said Miranda Porter, PhD, Senior Vice President, Clinical Development, Tokyo, who provides overall leadership for the Company's Japan operations.

"Our goal is to be the global 'CRO of Choice' in Japan, not only for customers but for employees as well. Our Japanese presence combines INC Research's global expertise and therapeutically-aligned delivery model along with local experience and knowledge regarding Japan's regulatory, healthcare, clinical trial site and cultural environments. This unique combination allows us to provide quality services to customers seeking to conduct global and regional studies in Japan, and also to attract exceptional Japanese employees who are interested in the opportunity to work for a global CRO. We look forward to the continued growth of INC Research within Japan."

Porter further added that the new Osaka office is located at 10th Floor Umeda Daibiru, 3-3-10 Umeda, Kita-ku, Osaka- Shi, Osaka 530-0001 and was chosen for its convenient location and proximity to the region's bullet train and major drug development areas.